{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04022213",
            "orgStudyIdInfo": {
                "id": "19-182"
            },
            "organization": {
                "fullName": "Memorial Sloan Kettering Cancer Center",
                "class": "OTHER"
            },
            "briefTitle": "A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum",
            "officialTitle": "Phase II Combination of 131I-Omburtamab Radioimmunotherapy and External Beam Radiotherapy for Desmoplastic Small Round Cell Tumor",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-study-of-the-drug-omburtamab-in-people-with-desmoplastic-small-round-cell-tumors-and-other-solid-tumors-in-the-peritoneum"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "startDateStruct": {
                "date": "2019-07-15",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-07",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-07",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2019-07-15",
            "studyFirstSubmitQcDate": "2019-07-15",
            "studyFirstPostDateStruct": {
                "date": "2019-07-17",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-26",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-27",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Memorial Sloan Kettering Cancer Center",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Y-mAbs Therapeutics",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to test any good and bad effects of the study drug 131I-omburtamab. 131I-omburtamab could prevent the cancer from returning, or delay the cancer from getting worse, but it could also cause side effects. Researchers hope to learn more about how 131I-omburtamab works in the body, and how effective it is in treating cancer. 131I-Omburtamab is not approved by the FDA to treat DSRCT or other cancers of the peritoneum."
        },
        "conditionsModule": {
            "conditions": [
                "Desmoplastic Small Round Cell Tumor",
                "Peritoneal Cancer",
                "Peritoneal Carcinoma"
            ],
            "keywords": [
                "Solid Tumor",
                "Peritoneal Solid Tumor",
                "DSRC",
                "I131-Omburtamab",
                "Memorial Sloan Kettering Cancer Center",
                "19-182"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 55,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Group A",
                    "type": "EXPERIMENTAL",
                    "description": "Participants with DSRCT who have undergone GTR of their abdominopelvic disease and who have no definitive radiological evidence of disease in liver or outside the abd/pelvis. Patients if deemed of likely benefit to the patient after completing IP RIT plus WAP-IMRT, or will be mandated if ANC is persistently \\<500/ul despite use of G-CSF for \\>1 week, or if patients experience life threatening febrile neutropenia.",
                    "interventionNames": [
                        "Drug: 131 I-omburtamab",
                        "Radiation: WAP-IMRT"
                    ]
                },
                {
                    "label": "Group B",
                    "type": "EXPERIMENTAL",
                    "description": "DSRCT patients who have macroscopic residual disease OR who have previously experienced progression of disease while on treatment but have subsequently had a GTR",
                    "interventionNames": [
                        "Drug: 131 I-omburtamab"
                    ]
                },
                {
                    "label": "Group C",
                    "type": "EXPERIMENTAL",
                    "description": "Participants with tumors other than DSRCT and will be enrolled onto an assessment arm to determine eligibility. Immunohistochemistry to assess B7H3 expression will be performed on frozen or paraffin embedded tissue using omburtamab (frozen tissue) or a commercially available anti-B7H3 antibody (if paraffin embedded).",
                    "interventionNames": [
                        "Drug: 131 I-omburtamab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "131 I-omburtamab",
                    "description": "Single dose of IP RIT administered through an IP catheter with 131 I-omburtamab at 80mCi/m2",
                    "armGroupLabels": [
                        "Group A",
                        "Group B",
                        "Group C"
                    ]
                },
                {
                    "type": "RADIATION",
                    "name": "WAP-IMRT",
                    "description": "Group A participants will receive WAP-IMRT approximately 2-4 weeks after completing IP RIT. A dose of 30 Gy will be delivered in 20 fractions of 1.5 Gy given once daily, 5 days per week over the course of approximately 4 weeks",
                    "armGroupLabels": [
                        "Group A"
                    ],
                    "otherNames": [
                        "Intensity Modulated Radiation Therapy"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Progression Free Survival/PFS",
                    "description": "Progression free survival after RIT + WA-IMRT.",
                    "timeFrame": "Up to 2 years after treatment is discontinued"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Have the diagnosis of DSRCT confirmed at MSKCC\n* Age \\>1 year and able to cooperate with radiation safety restrictions during therapy period.\n* Prior to intraperitoneal catheter placement\n\n  * At least 1 weeks must have elapsed since prior chemotherapy\n  * At least 2 weeks must have elapsed since biologic therapy\n  * Toxicities of prior therapy must have resolved to grade 1 or less or to the patient's baseline\n\nAt the completion of surgery, patients must fulfill all of the additional following criteria:\n\n* Have no definitive radiological evidence of disease active in liver or outside the abdomen/pelvic OR have had GTR of this disease at the time of catheter placement\n\nExclusion Criteria:\n\n* Prior progression of disease\n* Prior hypothermic intraperitoneal chemotherapy (HIPEC)\n* Cardiac, pulmonary, and neurologic toxicities are greater grade 1 per NCI CTCAE version 5\n* Renal, gastrointestinal, and hepatic, toxicities are greater than grade 2 (per NCI CTCAE version 5)\n* History of allergy to mouse proteins\n* Patients with grade 4 hypersensitivity reaction to radiolabeled iodine",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "1 Year",
            "stdAges": [
                "CHILD",
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Emily Slotkin, MD",
                    "role": "CONTACT",
                    "phone": "212-639-8856",
                    "email": "slotkine@mskcc.org"
                },
                {
                    "name": "Neeta Pandit-Taskar, MD",
                    "role": "CONTACT",
                    "phone": "212-639-3046"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Emily Slotkin, MD",
                    "affiliation": "Memorial Sloan Kettering Cancer Center",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Memorial Sloan Kettering Cancer Center",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10065",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Emily Slotkin, MD",
                            "role": "CONTACT",
                            "phone": "212-639-8856"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Memorial Sloan Kettering Cancer Center",
                    "url": "http://www.mskcc.org"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org."
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000058405",
                    "term": "Desmoplastic Small Round Cell Tumor"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000012509",
                    "term": "Sarcoma"
                },
                {
                    "id": "D000018204",
                    "term": "Neoplasms, Connective and Soft Tissue"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M29046",
                    "name": "Desmoplastic Small Round Cell Tumor",
                    "asFound": "Desmoplastic Small Round Cell Tumor",
                    "relevance": "HIGH"
                },
                {
                    "id": "M15327",
                    "name": "Sarcoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M20350",
                    "name": "Neoplasms, Connective and Soft Tissue",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "T1825",
                    "name": "Desmoplastic Small Round Cell Tumor",
                    "asFound": "Desmoplastic Small Round Cell Tumor",
                    "relevance": "HIGH"
                },
                {
                    "id": "T5284",
                    "name": "Soft Tissue Sarcoma",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                },
                {
                    "id": "M11110",
                    "name": "Liver Extracts",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Hemat",
                    "name": "Hematinics"
                }
            ]
        }
    },
    "hasResults": false
}